{rfName}
Cl

Indexed in

Citations

2

Altmetrics

Analysis of institutional authors

López, TlAuthorBlasco MAuthorCastro-Rebollo PAuthorSoy-Muner DAuthor

Share

December 5, 2024
Publications
>
Early Access
No

Clopidogrel-induced thrombotic microangiopathy: a case report

Publicated to: European Journal Of Hospital Pharmacy-Science And Practice. - 2024-07-04 (), DOI: 10.1136/ejhpharm-2024-004209

Authors: López, TL; Barceló, AFI; Gutiérrez, CG; Blasco, M; Grafia, I; Bastida, C; Castro-Rebollo, P; Soy-Muner, D

Affiliations

Hosp Clin Barcelona IDIBAPS, Med Oncol Dept - Author
Hosp Clin Barcelona, Pharm Dept, Div Med - Author
Hosp Univ Vic, Pharm Dept - Author
Inst Invest Biomed August Pi I Sunyer FRCB IDIBAPS, Fundacio Recerca Clin Barcelona - Author
Univ Barcelona, Hosp Clin Barcelona, Med Intens Care Unit, IDIBAPS - Author
See more

Abstract

Thrombotic microangiopathy is a serious condition that can be precipitated by exposure to certain medications. Although rare, it is life threatening and requires a high index of clinical suspicion, appropriate laboratory testing and immediate cessation of the offending agent. We present a case of a 75-year-old man with a history of ischaemic heart disease treated with clopidogrel and aspirin. One month after initiating the treatment he developed microangiopathic haemolytic anaemia and thrombocytopenia. Extensive clinical and laboratory investigations suggested thrombotic microangiopathy secondary to clopidogrel. The drug was immediately discontinued and treatment with intravenous corticosteroids was started. Within a week the patient's laboratory parameters normalised, indicating successful recovery. This case highlights the role of early detection and immediate discontinuation of suspected medication in the effective management of clopidogrel-induced thrombotic microangiopathy. Healthcare professionals should consider drug-induced thrombotic microangiopathy as a possible diagnosis in patients receiving clopidogrel who present with thrombocytopenia and microangiopathic haemolytic anaemia.

Keywords

AnemiaCritical careDiagnosiDrug-related side effects and adverse reactionsEmergency medicinEmergency medicineNephrologyThrombocytopenic purpuraTiclopidine

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal European Journal Of Hospital Pharmacy-Science And Practice due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position , thus managing to position itself as a Q2 (Segundo Cuartil), in the category Pharmacy. Notably, the journal is positioned en el Cuartil Q4 for the agency WoS (JCR) in the category Pharmacology & Pharmacy.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-12-15:

  • WoS: 1

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-12-15:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 1 (PlumX).

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Bladé Creixenti, Joan) and Last Author (Soy Muner, Dolors).